Navigation Links
YM sees nimotuzumab license unaffected by civil claim against licensor
Date:3/2/2010

ab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by Cytopia Ltd (now YM Australia) include the JAK 1/2 inhibitor CYT387, and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking stateme
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
3. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
4. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB APPROVED FOR MARKETING IN MEXICO
6. YM BIOSCIENCES USA RECEIVES CLEARANCE FROM US TREASURY DEPARTMENT TO EXTEND CLINICAL PROGRAM FOR NIMOTUZUMAB
7. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
8. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
9. YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING
10. YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER
11. YM BIOSCIENCES NIMOTUZUMAB SELECTED FOR MULTINATIONAL PHASE III TRIAL BY NATIONAL CANCER CENTRE OF SINGAPORE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , Sept. 1, 2015   Medfusion, Inc., ... the relationship between doctors and patients, today announced ... Durham, N.C. -based venture capital firms.   ... business association with Bull City Venture Partners and ... Medfusion Founder and Executive Chairman. "Both firms, experience ...
(Date:9/1/2015)... ... September 01, 2015 , ... GenoCAD, a leading provider ... version of its flagship DNA design platform, which has been enhanced to boost ... numerous genetic parts, which in turn can be recombined using specific sets of ...
(Date:8/31/2015)... ... August 31, 2015 , ... In ... its properties such as low carbon footprints and compostability. These properties can help ... based plastics. On the basis of applications, the market for biodegradable plastics can ...
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/53wxp3/israel_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.19 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology Technology:Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Israel Biomedical Sensors Market 2015 - Growth, Trends & Forecasts to 2020 2
... ABBOTT PARK, Ill. and SAN DIEGO , ... ) and Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... agreement to develop and commercialize elagolix for the treatment ... gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a ...
... , ... The mother of a previously healthy 20 year old woman found dead four ... United States Supreme Court case where the Court has been asked to bar ... the Court were to bar such lawsuits, manufacturers would have a lessened incentive ...
... 11, 2010 Researchers at Texas A&M University College of ... with the successful delivery of a foal using oocytes from ... The delivery of the foal highlights Texas A&M,s long tradition ... great experience for the owner of the new foal., "I,ve ...
Cached Biology Technology:Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 2Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 3Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 4Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis 5Supreme Court Amicus Brief Filed Opposing Lawsuit Protection for Manufacturers of Defectively Designed Vaccines 2Texas A&M veterinary researchers achieve cloning first 2Texas A&M veterinary researchers achieve cloning first 3
(Date:8/19/2015)...  VOXX International Corporation (Nasdaq: VOXX ) ... Definitive Agreement to purchase the assets, inclusive of ... EyeLock through an acquiring entity.  Upon consummation of ... in the acquiring entity. The closing of the ...  Expanding on its existing supply chain and distribution ...
(Date:8/12/2015)... 12, 2015 As the digital ... innovation and advanced biometrics technology is accelerating beyond expectations.  ... rely on using their credit cards, the digital currency, ... for payment services led by companies in the space ... Google, Inc. (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ...
(Date:8/10/2015)... The latest 364 page report from business intelligence provider ... border security market . Visiongain assesses that this ... Now: Border security is hard to achieve and harder to ... you need to know about - and more importantly, you ... this will impact your company and the border security industry ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... REDWOOD CITY, Calif., Dec. 2 DigitalPersona, Inc., a ... an agreement with IBM to deploy a new model ... 500 retail systems. The DigitalPersona U.are.U® 4500HD offering allows ... so that specific transactions can be linked to the ...
... of carbon about a nanometer in diameterhave been highly ... wires in molecular devices, or hydrogen storage components for ... at the National Institute of Standards and Technology (NIST) ... to the list: detection and destruction of an aggressive ...
... at the University of Southampton,s School of Ocean and ... (NOCS) has formally described four new species of king ... the new species in the Smithsonian Collections of the ... significance of the find, she said: "King crabs include ...
Cached Biology News:DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2King crab family bigger than ever 2
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
... Major Science Smart Minis 300V power ... with ever higher voltage, sufficient for SDS-PAGE, ... specifications ensure two pairs of terminator pairs ... Supply is designed for individuals to have ...
... NightOWL is a dedicated imaging system ... size. Equipped with a very sensitive camera ... or plants in tumor research, infectious disease ... Western blots. NightOWL is the only imager ...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Biology Products: